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ABSTRACT
The adenoviral gene E1a is known to enhance the antitumor effect of cisplatin, 
one of the cornerstones of the current cancer chemotherapy. Here we study the 
molecular basis of E1a mediated sensitivity to cisplatin in an experimental model 
of Non-small cell lung cancer. Our data show how E1a blocks the induction of 
autophagy triggered by cisplatin and promotes the apoptotic response in resistant 
cells. Interestingly, at the molecular level, we present evidences showing how the 
phosphatase MKP1 is a major determinant of cisplatin sensitivity and its upregulation 
is strictly required for the induction of chemosensitivity mediated by E1a. Indeed, 
E1a is almost unable to promote sensitivity in H460, in which the high expression of 
MKP1 remains unaffected by E1a. However, in resistant cell as H1299, H23 or H661, 
which display low levels of MKP1, E1a expression promotes a dramatic increase in the 
amount of MKP1 correlating with cisplatin sensitivity. Furthermore, effective knock 
down of MKP1 in H1299 E1a expressing cells restores resistance to a similar extent 
than parental cells.
In summary, the present work reinforce the critical role of MKP1 in the cellular 
response to cisplatin highlighting the importance of this phosphatase in future gene 
therapy approach based on E1a gene.
INTRODUCTION
The adenoviral protein E1a was primary described as 
an oncogene able to induce transformation in cooperation 
with other oncogenes such as Ras or Myc [1]. However, 
E1a also has an antitumor effect exerted by different 
mechanism as reversing the transformed phenotype, 
inhibiting metastasis, or inducing apoptosis in different 
experimental models [2–4] (for a review see [5]). From the 
therapeutic point of view is well stablished that E1a is able 
to promote radio/chemosensitivity [6–9]. In this regard, 
the ability of the adenoviral protein to induce sensitivity 
could be explained by different mechanisms. For 
example, the loss of function in the PI3K/AKT pathway 
has been proposed to be a key step in the induction of 
chemo/radiosensitivity [10, 11]. It is also known that this 
adenoviral protein is able to induce p53 stabilization [12] 
through binding to Mdm4, rendering Mdm2 inhibition 
and decreasing nuclear export and degradation of p53 
[13]. However, the chemosensitizer ability of E1a also 
has been reported to be p53 independent [14]. On the 
other hand, the effect exerted onto other critical tumor 
suppressors genes has been also proposed to be involved 
in E1a-induced chemosensitization, such p19ARF [12] 
or pRb. [15] In addition, proapoptotic protein as Bax and 
Caspase-9 [16–18] that ordinarily promotes cell death, 
could account for E1a associated sensitivity. It is also 
noteworthy that some of the biological properties of E1a 
are related to mitogen-activated protein kinases (MAPKs) 
signaling pathways. E1a is known to interfere with the 
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p38 pathway in response to different stimuli such as UV, 
chemo and radiotherapy playing an important role the 
inhibition of the PI3K/AKT pathway through the protein 
phosphatase PP2A [11, 19]. In addition, E1a is able to 
block ERK1/2 activation in fibroblast in the presence 
of v-H-Ras by increasing the levels of MKP1, a nuclear 
phosphatase for MAPK, explaining the ability of E1a to 
escape from Ras induced senescence [20]. Finally, E1a is 
also know to affect JNK in a Rac upstream manner but 
no phosphatase has been implicated in this case [21]. 
Nonetheless, all the previous suggest the important role 
that MAPKs and protein phosphatases could play in many 
of the biological properties controlled by E1a.
Non-small cell lung carcinoma (NSCLC) is a 
subtype of lung cancer, with a high ratio of refractory 
patients to the current therapy in which platin compounds 
are one of the cornerstones (for a review see [22]). 
Nonetheless, new approaches have been proposed to 
overcome cisplatin (cDDP) resistance, such as the use of 
glytazonas or copper chelators [23–25], aimed to improve 
platin based therapy, allowing a more selective use of the 
drug and avoiding some of the side effects. Interestingly 
an increase in the activity of the MAPKs has been linked 
with a more malignant phenotype. [26, 27]. In this regard, 
expression of MKP1, which is a key element to control 
the status of MAPKs pathways [28], has been shown to 
correlate with an improved survival for lung cancer [29].
In this scenario, we decided to study how E1a could 
promote chemosensitivity to cDDP in a panel of four 
NSCLC cell lines. Our results show how E1a, through 
the modulation of MKP1, promotes sensitivity in NSCLC 
derived cell lines, indicating that evaluation of MKP1 
could be a key element for future E1a gene-therapy 
protocols in order to exploit the chemosensitizer properties 
of this gene.
RESULTS
E1a enhances the antitumor effect of cDDP in 
NSCLC trough promotion of apoptosis
In order to study the E1a mediated sensitivity to 
cDDP we decided to use an experimental model comprised 
of 4 NSCLC derived cell lines with different genetic 
backgrounds (H460, H23, H661 and H1299) [30].  Cells 
were infected with lentivirus carrying the adenoviral 
gene E1a (isoform 13s) and resistance to cDDP was 
evaluated. After achieving a successful expression of E1a 
in our cell lines (Figure 1A), cells were exposed to the 
indicated doses of cDDP during 48 hours. E1a was able 
to increase the sensitivity to cDDP in all cell lines, being 
maximum in H1299 cells. However, H460 cells showed 
a minimum effect as judged by crystal violet (Figure 1B) 
and confirmed by MTT assay (Supplementry Figure S1). 
Furthermore, the induction of chemosensitivity was also 
evaluated for the E1a 12s isoform, promoting again a 
chemosensitivity phenotype even in the most resistant 
model, such as H1299 cells (Supplementry Figure S2).
To normalize the cytotoxic effect of cDDP in our 
panel of NSCLC we calculated the specific IC75, according 
to the data obtained at 48 hours, for each parental cell line 
in response to cDDP. Then we performed time course 
assays from 24 up to 120 hours (Figure 1C). As expected, 
we found that sensitivity associated to E1a was clear in 
H1299, H23 and H661 compared with H460, in which E1a 
associated sensitivity to cDDP was again almost marginal. 
As a result, we decide to study how E1a was 
affecting cell death mechanism triggered by cDDP in 
H1299 cells. As it is shown, (Figure 2A and 2B) E1a 
was able to promote an apoptotic response and blocks 
the induction of the characteristic autophagic response 
of resistant cells. Indeed, the use of QVD, a pan-caspase 
inhibitor [31], promotes a marked increase in the resistance 
of E1a expressing cells, but almost did not modify the 
response of the control cells (as it Figure 2C). Finally, 
autophagic flux was evaluated by using chloroquine [32]. 
As shown in Figure 2D, while in E1a expressing cells 
LC3 lipidation remains almost unaffected by the presence 
of chloroquine, non-expressing counterparts showed a 
marked increase in the lipidation of LC3, being consistent 
with a deregulation of the autophagic flux by the presence 
of E1a.
In summary, this set of data indicates that E1a is able 
to promote sensitivity by enhancing an apoptotic response 
to cDDP and blocking the characteristic induction of 
autophagy in our experimental model of H1299 cells.
Sensitivity to cDDP correlates with MKP1 
expression in NSCLC
Cellular response to cDDP has been connected with 
MAPKs signaling pathway (for a review see [33]). Among 
the several mechanisms to control MAPKs activity, protein 
phosphatases as MKP1 and DUSP5 are known targets 
of E1a [20]. Therefore, we decided to study the role of 
protein phosphatases in the chemosensitizer effect exerted 
by E1a in response to cDDP. Initially, we correlated the 
response of parental cell lines to cDDP (Figure 3A) with 
the expression levels by qRT-PCR of DUSP5 and MKP1 
(Figure 3B and 3C). As it is shown, different levels of 
intrinsic resistance showed a nice correlation with MKP1, 
but not with DUSP5. Next we validated this data by 
checking protein levels of MKP1 in our panel of NSCLC 
derived cell lines, showing again a nice correlation 
(Figure 3D). Furthermore, although we failed to detect 
JNK phosphorylation (data not shown), we found that 
the expression level of MKP1 nicely correlated with p38 
and ERK1/2 pathways activation in basal conditions, 
indicating the functionality of MKP1 expression [34].
To fully probe the role of MKP1 in the cellular 
response to cDDP in our NSCLC derived cell lines model, 
we decided to knockdown MKP1 in H460 cell line. After 
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Figure 1: E1a promotes sensitivity to cDDP in NSCLC. (A) H23, H1299, H460 and H661 were infected with empty vector or E1a 
13s. 50 µg of total cell lysates (TCL) were blotted against E1a. Membranes were reproved against Tubulin as loading control. (B) NSCLC 
cell lines with/without E1a 13s were treated with the indicated doses of cDDP during 48 hours and viability was evaluated by crystal violet 
method. Bars indicate standard deviation (SD). (C) NSCLC cells lines carrying empty vector or E1a 13s were treated with the IC75 obtained 
from Figure 1B during 5 days and viability was evaluated by crystal violet method. Bars indicate standard deviation (SD).
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Figure 2: E1a enhances the antitumor effect of cDDP in NSCLC trough promotion of apoptosis. (A) H1299 cells infected 
with E.V or E1a 13s were treated with 6 µg/ml of cDDP for 24 h and caspase 3/7 activity was evaluated. (B) H1299 cells infected with E.V 
or E1a 13s were treated with 6 µg/ml of cDDP for 48 h. Then, 50 µg of TCL were blotted against LC3 and p62. Membranes were reproved 
against tubulin as loading control. (C) Cells were treated as in (A) in the presence or absence of 10 μM Q-VD and then survival ratio was 
evaluated 48 hours later by using MTT assay. (D) H1299 cells infected with E.V. or E1a 13s were treated with chloroquine, in the absence 
of serum, at the indicated time points (time 0 means no chloroquine). Then 50 µg of TCL were blotted against LC3. Membranes were 
reproved against Tubulin as loading control.
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achieve an effective knock down at the mRNA and protein 
level (Figure 4A and 4B), we found that MKP1 abrogation 
induce resistance to cDDP (Figure 4C), supporting the 
key role of MKP1 in cDDP sensitivity. Furthermore, 
we also performed an alternative approach generating a 
H460 resistant cell line by continuous exposure to cDDP. 
Interestingly this new cell line showed a marked decrease 
in the levels of this phosphatase that correlates again with 
resistance (Figure 4D and 4E). 
Therefore, all these evidences support a critical role 
for MKP1 in the cellular response to cDDP, demonstrating 
how high levels of MKP1 correlate with sensitivity, while 
its suppression promotes resistance and suggesting that 
could be a potential mechanism to explain E1a associated 
chemosensitivity.
Upregulation of MKP1 mediates E1a associated 
sensitivity to cDDP
Next, we tested whether MKP1 protein levels, in our 
model of NSCLC, were affected by E1a gene. As shown 
in Figure 5A, all the resistant cell lines showed a clear 
increase in the levels of MKP1 in the presence of E1a, 
except for H460 cells in which the presence of E1a did 
not modify the expression level of MKP1. Functionality 
of MKP1 alteration was evaluated by means of p38MAPK 
phosphorylation, showing a marked decrease except in 
H460 cells (Figure 5A). 
To fully support our observations, we decided to 
abrogate MKP1 function in H1299 E1a expressing cells. 
Initially we tried some pharmacological approaches based 
on Ro 31–8220 [35] but renders an unacceptable toxicity 
Figure 3: Sensitivity to cDDP correlates with low expression of MKP1 in NSCLC. (A) NSCLC derived cell lines were treated 
with the indicated doses of cDDP during 48 hours and viability was evaluated by crystal violet method. Bars indicate standard deviation 
(SD). (B) H1299, H23, H661 and H460 were subjected to qRT-PCR assay in order to quantify DUSP5 mRNA expression levels. (C) Same 
approach was performed to measure MKP1 mRNA expression levels. (D) 50 µg of TCL from our panel of NSCLC cells were blotted 
against endogenous MKP1, p38MAPK and the respective active form. Tubulin was used as loading control.
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Figure 4: Abrogation of MKP1 mediates resistance to cDDP in NSCLC. (A) Expression of MKP1 was evaluated in H460 
infected with sh-RNA scrambled or MKP1 by qRT-PCR. (B) 50 µg of TCL from H460 cells infected with MKP1 sh-RNA or empty vector 
were blotted against MKP1. Tubulin was used as loading control. (C) H460 cell line infected with sh-RNA scrambled or MKP1 was treated 
with the indicated doses of cDDP during 48 hours and viability was evaluated by the crystal violet method. Bars indicate standard deviation 
(SD). (D) 50 µg of TCL from cDDP resistant H460 generated by co-culturing (cDDP-R) or parental H460 cell line were blotted against 
MKP1. Tubulin was used as loading control. (E) H460 cDDP-R or parental H460 were treated with the indicated doses of cDDP during 
48 hours and viability was evaluated by crystal violet method. Bars indicate standard deviation (SD).
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in our experimental model (Supplementry Figure S3). 
Therefore, we decided to use a genetic approach based 
on shRNA. As shown in Figure 5B and 5C, we achieved 
an effective knock down at the RNA and protein levels 
for MKP1 in E1a expressing cells, which again correlated 
with basal activation of p38MAPK and ERK1/2 signaling 
pathways, (Figure 5D) and restored resistance similar to 
control cells (Figure 5E).
Finally, to fully clarify the role of MAPKs in the 
chemosensitizer effect of E1a we took advantage of the 
specific inhibitors for both MAPK signaling pathway 
affected by E1a, ERK1/2 and p38MAPK, such as 
PD98059 and SB203580 [36, 37]. To this end, E1a 
expressing and non-expressing cells were incubated in the 
presence or absence of MAPK inhibitors with increased 
doses of cDDP. As shown (Figure 5F), the ERK1/2 
signaling pathway inhibitor did not modify significantly 
the response to cDDP, regardless the presence or absence 
of E1a. However, SB203580 (Figure 5G) promoted an 
increase in the sensitivity of E.V. that was not observed in 
E1a positive cells.
Taken together, these data indicate that, in E1a 
NSCLC expressing cells, upregulation of MKP1 and 
the subsequent p38MAPK inhibition is required for the 
induction of chemosensitivity to cDDP. In addition, the 
present data also suggest that  ERK1/2 signaling pathway 
is not directly implicated in the chemosensitizer effect 
associated to E1a
DISCUSSION
Several conclusions can be drawn from the present 
report.
First, E1a is able to promote sensitivity to cDDP in 
different models of NSCLC. This observation increases 
the list of tumor models in which E1a is able to induce 
chemosensitivity to cDDP as in the case of Squamous Cell 
Carcinoma or Ovarian cancer. [6, 38] Furthermore, this 
observation reinforces the universal character of E1a as 
therapeutic agent regardless of the tumor type. In addition, 
our observations indicate how E1a is able to promote 
chemosensitivity in different experimental models with 
different genetic patterns [30]. In this sense the tumor 
suppressor p53 has been considered as a master gene in the 
cellular response to cDDP since almost 20 years ago [39] 
with clinical implications as a bio marker for resistance 
to cDDP in lung cancer as well as in other pathologies 
[40–42]. Our data in H1299 cells, with a genetic lack 
of p53 gene, support the use of E1a as chemosensitizer 
agent in the presence of non-functional p53, which could 
account up to for 50% of human tumors. Even more, other 
genetic hallmarks of lung cancer such as mutant K-Ras 
[43], known to been implicated in cDDP resistance [44], 
seem to be not implicated in the effect exerted by  E1a, 
as the data in H23 cell line, with a mutant K-Ras gene 
[45], indicates. Therefore, our data supports the use of E1a 
as new universal chemosensitizer agent in lung cancer, 
especially in those cases with alterations in key genes 
that show an acute resistance. In addition, we consider 
that the evaluation of MKP1 expression, in agreement 
with previous reports that support the use of MKP1 as a 
biomarker in different types of tumors, [29, 46] could be 
key point in a future therapy based on E1a.
Regarding to MKP1 our data support how this 
phosphatase is a key player in the cellular response to cDDP 
and how cells with low levels of MKP1 have an intrinsic 
resistance to cDDP. In this sense, previous evidence 
supported MKP1 down-modulation as a mechanism 
to induce drug sensitivity in NSCLC [34, 47–49]. 
However in our experimental model of NSCLC we 
observed that low endogenous levels of MKP1 correlates 
with a marked “de novo” resistance. In agreement with 
this observation, E1a increases the level of MKP1 to 
promote sensitivity. In addition is noteworthy that E1a 
is not only affecting MKP1 dependent signaling, other 
pathways, as the PI3K/AKT pathway [10], could be 
modulated by E1a to account for the chemosensitive 
phenotype observed. In this regard, considering that 
MAPKs are the natural substrates of MKP1, our data 
support a role for p38MAPK in the chemosensitizer 
effect of E1a. Indeed, the p38MAPK signaling pathway, 
also known to be a target of E1a, is related to cDDP 
response [11, 19] and is noteworthy that recent evidence 
supports that  the inhibition of p38MAPK is able to 
promote sensitivity to cDDP [50], in agreement with our 
observation in the context of E1a expression. However 
our data do not support a direct implication of the 
ERK1/2 in the chemosensitizer effect of E1a, in spite of 
being a signaling pathway targeted by E1a [20, 51] and 
related to cDDP resistance [52, 53]. Nonetheless, other 
mechanisms should be considered to fully explain the 
role of MKP1 in the cellular response to cDDP in the 
presence of E1a. For example, it is well stablished that 
NF-kb inhibition mediates chemosensitivity [54, 55] and 
its activation correlates with resistance [56]. Interestingly, 
NF-kb pathway is also targeted by E1a [57] and recent 
evidences showed an inverse correlation between MKP1 
expression and NF-kb activity [58] which could account 
for our observations in E1a associated sensitivity. 
Furthermore, possibilities as deregulation in proteins like 
RIP [59] could account for the chemosensitizer effect of 
E1a if mediated trough NF-kb, especially considering 
the relationship between E1a and the JNK signaling 
pathway [21]. Therefore, further studies are required to 
fully elucidate the mechanism affected by E1a to promote 
cDDP sensitivity. In addition, is interesting to mention 
how the upregulation of MKP1 has been considered as 
a critical step in novel therapeutic approaches for lung 
cancer, as in the case of K-Ras driven lung carcinogenesis 
and γ-secretase [60].
Finally is important to mention that E1a is able to 
promote cDDP sensitivity trough an increase in apoptosis, 
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Figure 5: Upregulation of MKP1 mediates E1a associated sensitivity to cDDP in a p38MAPK dependent fashion. 
(A) 50 µg of the TCL from NSCLC expressing E1a 13s or empty vector were used to evaluate the MKP1, P-p38MAPK and p38MAPK. 
Tubulin was used as loading control. (B) H1299 stably transfected with pcDNA E1a 13s (H1299 E1a) or empty vector (E.V.) were infected 
with lentivirus carrying  sh-RNA against MKP1 (H1299 E1a shMKP1) and then mRNA MKP1 levels were evaluated by qRT-PCR. 
(C) 50 µg of TCL from cells used in B) were blotted against MKP1 and E1a. Tubulin was used as loading control. (D) 50 µg of TCL from 
cell used in C) were blotted against p38, ERK1/2 and the respective active forms. Tubulin was used as loading control. (E) H1299 E.V, 
H1299 E1a and H1299 E1a and sh-RNA MKP1 were treated with the indicated doses of cDDP during 48 hours and viability was evaluated 
by crystal violet method. Bars indicate standard deviation (SD). (F) H1299 E.V and H1299 E1a were treated with the indicated doses of 
cDDP during 48 hours in the presence/absences of PD98059 (10 µM). Viability was evaluated by crystal violet method. Bars indicate 
standard deviation (SD). (G) H1299 E.V and H1299 E1a were treated with the indicated doses of cDDP during 48 hours in the presence/
absences of SB203580 (10 µM). Viability was evaluated by crystal violet method. Bars indicate standard deviation (SD).
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that correlates with a blockage of the autophagic 
response associated to cDDP resistance [61, 62]. 
This issue raises the possibility that E1a could be a novel 
negative modulator of autophagy associated to cDDP 
by promoting apoptosis. However, it has been proposed 
that E1a plus E1b are required for adenovirus associated 
autophagy [63]. In this sense our data show how cells 
expressing only E1a showed an apparent increase in 
the basal flux of autophagy, by means of higher level 
of LC3 lipidated and low p62 levels  as well as the lack 
of response to chloroquine. Therefore, this deregulated 
basal autophagic flux could explain the observed lack of 
an apparent autophagic response in case of H1299 E1a 
expressing cells. Nonetheless this hypothesis, as well as 
the implication of MKP1 in a putative deregulation in the 
basal autophagy flux, needs to be further investigate to 
fully stablish the role of E1a in autophagy.
In summary, here we present evidences showing 
how MKP1 upregulation is a critical event in E1a 
associated sensitivity to cDDP in a NSCLC experimental 
model. This effect is independent of key genes in lung 
carcinogenesis as p53 or K-Ras and is mediated with an 
increase in the cDDP triggered apoptosis. Therefore, our 
data support the use of E1a gene in future therapeutic 
approaches for lung cancer, specifically in cDDP resistant 
tumors. Whether our observation could be extrapolated 
to other type of tumors or therapeutic agents need to be 
deeply investigated.  
MATERIALS AND METHODS
Cell lines and plasmids
Non-small lung cancer cells (H23, H460, H661 
and H1299) were maintained in DMEM supplemented 
with 10% FBS plus antibiotics (Sigma-Aldrich, Tres 
Cantos, Madrid, Spain). Cells were maintained in 5% 
CO2 and 37°C. H460 and H1299 cell lines were purchased 
from ATCC (LGC Promochem, Barcelona, Spain). H23 
and H661 cell lines were kindly provide by Dr. R. Pio 
(Department of Biochemistry, School of Sciences. 
University of Navarra, Pamplona, Spain). All these cell 
lines have been previously described [64].
To generate H460 resistant cell line by co-culturing 
with cDDP, cells were routinely maintained with different 
concentration of cDDP (ranging from 0.1 µg/mL to 
0.8 µg/mL) during 2 months. After that, the H460 cells 
that were able to survive in the highest concentration of 
cDDP (0.2 µg/mL) were used for further experiments.
E1a isoform 13s was obtained by PCR from 
cDNA of 293T cells and cloned in PCDNA3.1 and 
then subcloned into pLESIP vector. This construct 
has been previously described [9]. pLESIP-E1a 12s 
was obtained by PCR cloning from pLPC vector 
kindly provided by Dr. Scott Lowe’s lab (Memorial 
Sloan-Kettering Cancer Center, New York, New 
York USA). PCR Primers used were; forward 5′- 
GTGGATCCATGAGACATATTATCTGCC-3′ and reverse 
5′-GGGAATTCTTATGGCCTGGGGCGTTTAC-3′. PCR 
conditions were 94°C 30 sec. during the first cycle and 
then, 30 cycles (94°C 30 sec, 52°C 1 min and 72°C 3 min) 
with a final extension of 72°C during 10 min. After 
sequencing and expression assay, E1a 12s was cloned, 
using the BamH1/EcoR1 sites, onto pLESIP vector.
Chemicals and antibodies
Antibodies against active form of p38 as well as 
total p38 were from Cell Signaling Technologies (Izasa, 
Barcelona , Spain).  Antibodies against E1a, p62, MKP1 
and tubulin were purchased from Santa Cruz Technology 
(Quimigen, Madrid, Spain). Antibody against LC3 was 
from Sigma Aldrich (Tres Cantos, Madrid, Sapin). cDDP 
was purchased from Ferre Farma (Barcelona, Spain) and 
prepared freshly before use. The inhibitors for MKP1, 
(Ro 31–8220 Mesylate), p38MAPK (SB 203580) and 
ERK1/2 (PD098059) were purchased from Selleckchem 
(DeltaClon, Madrid, Spain), dissolved in DMSO at 10 mM, 
aliquoted and stored at −20°C.
Transfections and infections
Lentiviral production and infection was performed as 
previously described [9, 64]. Briefly, HEK293T cells were 
transfected overnight using calcium phosphate with 9 µg of 
pLESIP E1a 13s, pLKO-shRNA for MKP1 or pLKO empty 
vector plus 6µg of PSPAX2, and 3 µg of the viral envelope 
protein (VSVG). Supernatant was collected 48 hours after 
transfection. Host cells were infected by adding packaging 
cells media in the presence of 4 µg/ml polybrene from 
Sigma-Aldrich. 48 hours after infection cells were exposed 
to 2 µg/ml of puromycin (Sigma-Aldrich) for H460, 1 µg/
ml for H23, 1 µg/ml for H661 and 3 µg/ ml for H1299 cells, 
for at least 3 days before any assay. Infected cells were 
routinely maintained at the appropriate concentrations of 
puromycin.
Transfection of pCDNA3 E1a 13 was performed 
with 2 μg of the plasmid by using lipofectamine 2000 
(Invitrogen, Barcelona Spian). After 48 h, cells were 
selected with G418 (Sigma-Aldrich) at 800 μg/ml, for at 
least 10 days, prior any assay.
Western blotting
Cells were collected in lysis buffer (100 mM 
HEPES, pH 7.5, 50 mM NaCl, 0,1% Triton X-100, 5 mM 
EDTA, 0.125 M EGTA). Protease and phosphatase 
inhibitors (0.2 µg/ml Leupeptin, 2 µg/ml, Aprotinin, 1 mM 
PMSF and 0.1 mM Na3VO4) were added prior to lysis. 
Protein quantification was performed by using the BCA 
Protein Assay Kit (Pierce, Madrid, Spain) following the 
manufacturer’s instructions. Indicated amounts of protein 
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were loaded onto 10% SDS-PAGE, transferred to PVDF 
membranes and blotted against different proteins using 
specific antibodies.
Antibody detection was achieved by enhanced 
chemiluminescence (Amersham, GE Health Care, 
Barcelona, Spain) in a LAS-3000 system (FujiFilm, Japan). 
Results show a representative blot out of three with nearly 
identical results. Tubulin was used as a loading control. 
Images show a representative experiment out of 3, with 
nearly identical results. Quantification was performed by 
using NIH ImageJ software.
RNA isolation, reverse transcription and 
quantitative real-time PCR
Total RNA was obtained and reverse transcription 
was performed as previously described [65]. Changes 
in the mRNA expression of MKP1 and DUSP5 were 
examined by Quantitative Real-Time PCR using an 
ABIPrism 7500 FAST Sequence Detection System 
(Applied Biosystems, Madrid, Spain). cDNA was 
amplified using SYBR Green I PCR Master Mix (Applied 
Biosystems) in the presence of specific oligonucleotides. 
The PCR conditions and quantification was performed as 
previously described. [65] Primers for all target sequences 
were designed using the computer Primer Express 
software specially provided with the 7000 Sequence 
Detection System (Applied Biosystems). PCR primers 
were purchase from Bonsai Technologies (Madrid, Spain). 
For MKP1: forward 5′-AGCCACCATCTGCCTT 
GCTTA-3′; reverse ′5′-CTGGCCCATGAAGCTGAAG 
TT-3′.
For DUSP5: forward 5′-CGGAATATCCTGAGTG 
TTGCG-3′ - reverse 5′-CACTTGGATGCATGGTAGG 
CA-3′ and for GAPDH: forward 5′-TCGTGGAAGGACTC 
ATGACCA-3′, reverse 5′-CAGTCTTCTGGGTGGCAG 
TGA-3′. Data are the average of, at least, three 
independent experiments performed in triplicate.
Interference assays
Plasmids containing the sh-RNA for MKP1 were 
purchased from Sigma-Aldrich (SHCLND-NM_004417) 
and used following the manufacturer’s recommendations 
as previously described [62]. Five different clones were 
tested and best performing clone was selected for further 
experiments.
Viability assays
Viability was evaluated by crystal violet method and 
confirmed by MTT assay [62]. For crystal violet method, 
cells were seeded 24 hours prior drug treatment at 2 × 104 
cells/well. Colorant was recovered using 1% acetic acid 
and optical density was evaluated at 590 nm. Values were 
referred to untreated controls. Data are the average of at 
least 3 independent experiments performed in triplicate 
cultures.
The MTT assay were performed with a 2 × 104 
cells/well plated in 24-well plates and then exposed to 
tested agents. MTT reactant (Thiazolyl Blue Tetrazolium 
Bromide, M2128, Sigma Aldrich), at 5 mg/ml in a PBS 
solution, was added to the cells in a 1:10 ratio (MTT 
solution:culture medium) and left for incubation during 
1 h at 37°C. After removal of the medium, DMSO was 
added to each well to dissolve the formazan crystals. The 
absorbance at 540 nm was determined using a Biokinetics 
plate reader (Bio-Tek Instruments, Inc, Winooski, VT, 
USA). Data are the average of at least 3 independent 
experiments performed in triplicates cultures.
Apoptosis assays
For caspase 3/7 assays, cells were plated at a density 
of 104 cells/well in opaque 96-well plates 24 hours prior 
to treatment. 24 hours after treatment, activation of 
effector caspases 3 and 7 was evaluated with Promega’s 
CaspaseGlo kit (G8090) as previously described [62]. 
Resulting mixtures were quantified after 30 minutes of 
incubation at room temperature in a Beckton Dickinson 
BD 3096 luminometer. Data are the average of at least 3 
independent experiments performed in triplicates cultures. 
Statistical analysis
Data are presented as mean ± S.D. Statistical 
significance was evaluated by Student’s t test using the 
GraphPad Prism 5.00 software. The statistical significance 
of differences was indicated in figures by asterisks as 
follows: *P < 0.05, **P < 0.01 and ***P < 0.001.
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